Victoria Korneva*, Tatiana Kuznetsova and Ulrich Julius Pages 3841 - 3857 ( 17 )
Patients who have achieved very low low-density lipoprotein CH (LDL-C) levels in clinical trials have shown the lowest cardio-vascular risk. The current clinical guidelines set such a concentration for LDL-C as < 1.4 mmol/L. However, the question of minimum permissible target values of the lipids remains unresolved. A number of experimental and clinical studies showed some unfavorable consequences of low LDL-C levels At the same time, the modern arsenal of lipid lowering drugs allows reducing LDL-C levels to extremely low values. This review presents an analysis of literature about the safety of low lipid spectrum parameters.
Low-density lipoprotein CH (LDL-C), PCSK9 inhibitors, statins, diabetes mellitus, immune system, malignant neoplasms, brain function.
Petrozavodsk State University, Faculty Therapy Department, 185000 Lenin Ave., 33, Petrozavodsk, Petrozavodsk State University, Faculty Therapy Department, 185000 Lenin Ave., 33, Petrozavodsk, Lipidology and Lipoprotein Apheresis Center, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universtät Dresden, Fetscherstr. 74, 01307 Dresden